V. Butterweck, Mechanism of Action of St John???s Wort in Depression, CNS Drugs, vol.3, issue.3, pp.539-562, 2003.
DOI : 10.2165/00023210-200317080-00001

V. Butterweck and M. Schmidt, Johanniskraut ??? Beitr??ge der Inhaltsstoffe zu Wirkmechanismen und Wirksamkeit, Wiener Medizinische Wochenschrift, vol.72, issue.Suppl 1, pp.356-361, 2007.
DOI : 10.1007/s10354-007-0440-8

P. Zanoli, Role of Hyperforin in the Pharmacological Activities of St. John's Wort, CNS Drug Reviews, vol.71, issue.Suppl 1, pp.203-218, 2004.
DOI : 10.1111/j.1527-3458.2004.tb00022.x

V. Butterweck, A. Nahrstedt, J. Evans, S. Hufeisen, L. Rauser et al., In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs, Psychopharmacology, vol.162, issue.2, pp.193-202, 2002.
DOI : 10.1007/s00213-002-1073-7

M. Melzer, D. Fuhrken, and R. Kolkmann, Hyperforin im Johanniskraut ? Hauptwirkstoff oder nur Leitsubstanz?, Dtsch Apoth Ztg, vol.138, pp.56-62, 1998.

R. Madabushi, B. Frank, B. Drewelow, H. Derendorf, and V. Butterweck, Hyperforin in St. John???s wort drug interactions, European Journal of Clinical Pharmacology, vol.77, issue.2, pp.225-233, 2006.
DOI : 10.1007/s00228-006-0096-0

G. De-los-reyes and R. Koda, Determining hyperforin and hypericin content in eight brands of St. John's wort, Am J Health Syst Pharm, vol.59, pp.545-547, 2002.

A. Draves and S. Walker, Analysis of the hypericin and pseudohypericin content of commercially available St. John's wort preparations, Can J Clin Pharmacol, vol.10, pp.114-118, 2003.

M. Wurglics, K. Westerhoff, A. Kaunzinger, A. Wilke, A. Baumeister et al., Comparison of German St. John's Wort Products According to Hyperforin and Total Hypericin Content, Journal of the American Pharmaceutical Association (1996), vol.41, issue.4, pp.560-566, 2001.
DOI : 10.1016/S1086-5802(16)31280-3

E. Schrader, Equivalence of St John??s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mildmoderate depression, International Clinical Psychopharmacology, vol.15, issue.2, pp.61-68, 2000.
DOI : 10.1097/00004850-200015020-00001

H. Woelk, Comparison of St John's wort and imipramine for treating depression: randomised controlled trial, BMJ, vol.321, issue.7260, pp.536-539, 2001.
DOI : 10.1136/bmj.321.7260.536

D. Whitten, S. Myers, J. Hawrelak, and H. Wohlmuth, The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials, British Journal of Clinical Pharmacology, vol.67, issue.5, pp.512-526, 2006.
DOI : 10.1067/mcp.2002.124080

M. Mannel, Drug Interactions with St John???s Wort, Drug Safety, vol.1, issue.3, pp.773-797, 2004.
DOI : 10.2165/00002018-200427110-00003

D. Dürr, B. Stieger, G. Kullak-ublick, K. Rentsch, H. Steinert et al., St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4, Clinical Pharmacology & Therapeutics, vol.68, issue.6, pp.598-604, 2000.
DOI : 10.1067/mcp.2000.112240

L. Moore, B. Goodwin, S. Jones, G. Wisely, C. Serabjit-singh et al., St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor, Proceedings of the National Academy of Sciences, vol.97, issue.13, pp.7500-7502, 2000.
DOI : 10.1073/pnas.130155097

J. Wentworth, M. Agostini, J. Love, J. Schwabe, and V. Chatterjee, St John's wort, a herbal antidepressant, activates the steroid X receptor, Journal of Endocrinology, vol.166, issue.3, pp.11-16, 2000.
DOI : 10.1677/joe.0.166R011

U. Gödtel-armbrust, A. Metzger, U. Kroll, O. Kelber, and L. Wojnowski, Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John???s wort, Naunyn-Schmiedeberg's Archives of Pharmacology, vol.18, issue.6, pp.377-382, 2007.
DOI : 10.1007/s00210-007-0172-8

S. Mueller, J. Majcher-peszynska, B. Uehleke, S. Klammt, R. Mundkowski et al., The extent of induction of CYP3A by St. John???s wort varies among products and is linked to hyperforin dose, European Journal of Clinical Pharmacology, vol.18, issue.1, pp.29-36, 2006.
DOI : 10.1007/s00228-005-0061-3

I. Mai, S. Bauer, E. Perloff, A. Johne, B. Uehleke et al., Hyperforin content determines the magnitude of the St John's wort???cyclosporine drug interaction, Clinical Pharmacology & Therapeutics, vol.76, issue.4, pp.330-340, 2004.
DOI : 10.1016/j.clpt.2004.07.004

G. Arold, F. Donath, A. Maurer, K. Diefenbach, S. Bauer et al., No Relevant Interaction with Alprazolam, Caffeine, Tolbutamide, and Digoxin by Treatment with a Low-Hyperforin St John???s Wort Extract, Planta Medica, vol.71, issue.4, pp.331-337, 2005.
DOI : 10.1055/s-2005-864099

S. Huang, R. Temple, D. Throckmorton, and L. Lesko, Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling, Clinical Pharmacology & Therapeutics, vol.329, issue.2, pp.298-304, 2007.
DOI : 10.1038/sj.clpt.6100054

F. Gaedcke, Johanniskraut und dessen Zubereitungen, Dtsch Apoth Ztg, vol.137, pp.3753-3757, 1997.

J. Hölzl and E. Ostrowski, Johanniskraut (Hypericum perforatum ): HPLC-Analyse der wichtigen Inhaltsstoffe und deren Variabilität in einer Population, Dtsch Apoth Ztg, vol.127, pp.1227-1230, 1987.

W. Miekisch, P. Fuchs, A. Berg, G. Nöldge-schomburg, B. Drewelow et al., An improved GC/MS method for the determination of midazolam in human plasma [abstract], Int J Clin Pharmacol Ther, vol.4, p.560, 2003.

B. Ring, B. Patterson, M. Mitchell, M. Vandenbranden, J. Gillespie et al., Effect of tadalafil on cytochrome P450 3A4?mediated clearance: Studies in vitro and in vivo, Clinical Pharmacology & Therapeutics, vol.77, issue.1, pp.63-75, 2005.
DOI : 10.1016/j.clpt.2004.09.006

B. Johnson, I. Song, K. Adkison, J. Borland, L. Fang et al., Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail, The Journal of Clinical Pharmacology, vol.31, issue.5, pp.577-587, 2006.
DOI : 10.1177/0091270006287291

Z. Wang, C. Gorski, M. Hamman, S. Huang, L. Lesko et al., The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity, Clinical Pharmacology & Therapeutics, vol.70, issue.4, pp.317-326, 2001.
DOI : 10.1016/S0009-9236(01)17221-8

G. Dresser, U. Schwarz, G. Wilkinson, and R. Kim, Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects, Clinical Pharmacology & Therapeutics, vol.73, issue.1, pp.41-50, 2003.
DOI : 10.1067/mcp.2003.10